The Influence of Stabilizers on Brucella abortus RB51
DOI:
https://doi.org/10.61841/ab9kbx08Keywords:
Brucella abortus, RB51 vaccine,stabilizer stability, ELISA, IFN-ƔAbstract
--Brucella abortus is one of the most important pathogenic brucella species, RB51 B.abortus vaccine is the best available vaccine used to control and prophylactic of brucellosis, RB51 is live attenuated lyophilized vaccine during freeze drying the bacterial cells exposed to stress due to the lypholization steps which overcomes by using of stabilizers that added to protect the bacterial cells from this stress. Therefore this study was conducted to evaluate the efficacy of skimmed milk and WHO as stabilizing compounds for preparation of B.abortus RB51 vaccines and evaluate their humoral and cellular immunity by immunizing the mice with the prepared vaccines .the sera samples were tested by I-ELISA assay and the spleen samples were measured for IFN-Ɣ as indicator of cellular immunity then, the results were compared with the licensed RB51 vaccine.
Downloads
References
1. Alton,G.G.;Jones,L.M.;Angus R.D.; and Verger, J.M, 1988. "Techniques for the brucellosis
2. Laboratory.Paris,France:Institute National de La Recherche Agronomique,17-136.
3. Barbour EK, Hamadeh SK, Bajjani NE, Faroon OM, Eid A, Sakr W, et al. Immunopotentiation of a developed Salmonella enterica serotype Enteritidis vaccine by thymulin and zinc in meat chicken breeders. Vet Res Commun 2001;25:437–47
4. Bhattacharjee AK, Van de Verg L, Izadjoo MJ,Yuan L,Hadfield TL, Zollinger WD and Hoover
5. DL, 2002. Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharides as a non-covalent complex with Neisseria meningitides Group
6. B outer membrane protein. Infect Immun, 70:3324-3329.
7. Blasco JM, 1990. Brucella ovis.In:Animal brucellosis.Edited by Nielsen K and JR Duncan.CRC Press, Florida, USA, 351-378.
8. Corbel, M. J. 1997:” Brucellosis: an overview.” Emerg Infect Dis. 3:213-21
9. Corbel, M.J. 2006.Brucellosis in humans and animals. WHO/CDS/EPR/2006.7
10. Dorneles EMS, Oliveria LF and Lage AP. (2017) “Brucella Abortus Vaccines: Use in Control
11. Programs and Immune Response.” J Bacteriol Mycol. 4(1): 1044.
12. Dorneles EM, Carvalhob AT, Araújob MS, Sriranganathan N., Lagea A.P.(2015)
13. “Immune response triggered by Brucella abortus following infection or vaccination.”.
14. Vaccine 33 . 3659–3666
15. Galanos.C.;Luderitz,O.;westphal,O.(1969):"A New method for extraction of R
16. lipopolysaccharide." Eur.J.Biochem.1969,9,245-249.
17. Janeway CA.,Travers P,Walport M, and Capra JD,1999. Immunobiology: the immune system in health, 4th ed. Current Biology Publications, London.ations, London.
18. Knezevic I (2009). Stability evaluation of vaccines: WHO approach. Biologicals 37(6): 357–359.
19. Khokha R, Werb Z, 2011. Mammary gland reprogramming: metalloproteinase couple form with
20. function ,Cold Spring Harb Perspect Biol 3:4333.
21. Lo´pez-Gon˜I D, García-Yoldi CM, Marín MJ,de Miguel PM, Mun˜oz, JM. Blasco I, Jacques
22. M, Grayon A, Cloeckaert AC, Ferreira R, Cardoso MI, Correˆa de Sa K, Walravens A D, and Garin- Bastuji B, 2008. Evaluation of a Multiplex PCR Assay (Bruce-ladder) for
23. Molecular Typing of All Brucella Species, Including the Vaccine Strains, J Clin Microbiol, p. 3484– 3487 Vol. 46, No. 100095-1137/08/$08.00_0 doi:10.1128/JCM.00837-08
24. Morefield G., AAPS J. 13,191i-200, 2011. https://doi.org/ 10.1208/s12248-011-9261-1.
25. Moriyon I, Grillo MJ, Monreal D, Gonzalez D, Marin C,Lopez-goni I, Mainar-Jaime R, Moreno E and Blasco JM, 2004. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res 35:1–38 .
26. Neha Dabra , NeetaJain-Gupta , MohamedN.Seleem, NammalwarSriranganathan and
27. RameshVemulapalli, 2015. Overexpression of Brucella putative glycosyl transferase WbkA in B.abortus RB51 leads to production of exopolysaccharide” Original Research published:
28. 24June2015 doi: 10.3389/fcimb.2015.00054.
29. Nielsen, K., P. Smith, W. Yu, P. Nicoletti, P. etal. 2004. “Enzyme immunoassay for the diagnosis of brucellosis: chimeric Protein A–Protein G as a common enzyme labeled detection.”
30. Nielsen O, Nielsen K, Braun R.and Kelly L ,2005. Acomparison of four serologic assays in screening for Brucella exposure in Hawaiian monk seals. J. Wildi. Dis., 41(1):126-133.
31. OIE. Bovine Brucellosis Manual of diagnostic tests and vaccines for terrestrialanimals. World Organisation for Animal Health; 2016.
32. OPS Diagnostics will host a free webinar entitled "A Primer on Freeze Drying of
33. Microorganisms", on Wednesday, February 17, 2016, at 2:00 PM (EST).
34. Pappas G, Papadimitriou P, Christou L , Akritidis N , Tsianos EV,2006. The new global map of human brucellosis. Lancet Infect.Dis.6:91-99.
35. Pasquali,P.;Rosanna,A.;Pistoia,C.;Petrucci,P.and Ciuchini,F, 2003."Brucella abortus RB5induces protection in mice orallyinfected with the virulent strain B.abortus 2308."
36. Radostits OM , Gay CC ,Blood DC and Hinchcliff KW, 2000. Veterinary Medicine , 9th ed.
37. ELBS Bailliere Tindall, London, Philadelphia.pp:870-871.
38. Salmani AS, Siadat SD, Ahmadi H, Nejati M, Norouzian D, Tabaraie B, Abbasi M, Karbasian
39. M, Mobarez, AM. and Shapouri, R, 2008. Optimization of Brucella abortus S99
40. lipopolysaccharide extraction by phenol and butanol methods.Res. J. Biol. Sci., 3:576-580
41. Santis RD, Ciammaruconi A, Pomponi A ,Fillo S , Lista F ,2011. Brucella: molecular diagnostic techniques in response to bioterrorism threat.J Bioterr Biodef S2:004 .
42. Schurig,G-G;Roop II,R.M.;Bagchi,T.;Boyle,s.;Buhrman,D.and sriranganathan,N.(1991):
43. "Biological properties of RB51;a stable rough strain of Brucella abortus."Veterinary Microbiology 28(2):171-188.
44. Stevens, M. G., S. G. Hennager, S. C. Olsen, and N. F. Cheville. (1994) "Serologic responses in diagnostic tests for brucellosis in cattle vaccinated with Brucella abortus 19 or RB51." J Clin Microbiol 32:1065-6.
45. Teane M. A. Silva, Erica A. Costa, Tatiane A. Paixao, Renee M. Tsolis, and Renato L. Santos, 2011
46. Laboratory Animal Models for Brucellosis Research,Journal of Biomedicine and Biotechnology .
47. Warthen R.M, Salisbury MD (US); Gully C.P., Salisbury MD (Us) (2008) “Non- animal origin stabilizers and processes for producing the same.” US 7,435,422 B2 Oct. 14, 2008.
48. World 8Health Organization. (WHO) Laboratory Safety Manual.3rd ed. Geneva, Switzerland, 2004.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
